Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if a combination of Palbociclib and Sunitinib is safe and effective in various solid tumors.
The main questions it aims to answer are:
* Is the drugs combination safe for the participants?
* Is the drug combination effective in all solid malignancies? It is a single arm study, phase 1b/2, dose escalation and expansion, to determine the safety, tolerability and initial efficacy of this combination.
Participants will:
* Take the drugs combination every day for 5 executive days, and 2 days of, in a 28 days cycle, for up to a year.
* Visit the clinic once every 2 weeks for checkups and tests